Alison Handley
Takeda Pharmaceutical Company
8 Papers
23 Citations
Alison Handley is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Azilsartan Medoxomil & Medicine. The author has an hindex of 5, co-authored 8 publications.
Chat about Author
Papers
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
Domenic A. Sica,William B. White,Michael A. Weber,George L. Bakris,Alfonso Perez,Charlie Cao,Alison Handley,Stuart Kupfer +7 more
TL;DR: This poster presents a probabilistic procedure to assess the importance of baseline IgE levels in the decision-making process for ART and its applications in the context of ART-informed medicine.
103
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
George L. Bakris,Domenic A. Sica,William B. White,William C. Cushman,Michael A. Weber,Alison Handley,Eric Song,Stuart Kupfer +7 more
TL;DR: Chlorthalidone combined with azilsartan medoxomil provides better blood pressure reduction and a higher likelihood of achieving blood pressure control than hydrochlorothiazide combined with Azilsarta medoxOMil.
86
Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
G Bönner,George L. Bakris,D Sica,Michael A. Weber,William B. White,Alfonso Perez,Charlie Cao,Alison Handley,Stuart Kupfer +8 more
TL;DR: Treatment of stage 1–2 hypertension with Azilsartan medoxomil was more effective than RAM and better tolerated, and data demonstrated that treatment of stage 2–3 hypertension with AZL-M was more Effective and Better tolerated.
Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide.
TL;DR: Fixed‐dose combination AZL‐M/CLD showed an encouraging benefit‐risk profile when used per standard clinical practice in a titrate‐to‐target strategy and was maintained throughout the study, despite less uptitration.
14
Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study
TL;DR: It is demonstrated that AZL-M is well tolerated over the long term and provides stable BP improvements when used in a treat-to-target BP approach with thiazide-type diuretics.
10